Smashed Peaches

Drug Research Studies

DC seeks legal mushrooms – NWAOnline

WASHINGTON — Activists in Washington presented more than 36,000 signatures to the Board of Elections for a November ballot initiative in the nation’s capital that would decriminalize psilocybin “magic” mushrooms and other natural psychedelics like mescaline.

If passed, it would be the first of its kind for an Eastern city; Denver became the first U.S. city to pass such an initiative in May 2019, with the California cities of Oakland and Santa Cruz following suit. It would also likely face efforts in Congress to overturn or block its implementation.

Activists are deemphasizing the recreational aspects of the drugs, focusing on the therapeutic and medical benefits as treatment for depression, trauma and addiction.

“D.C. could really lead the way on this,” said campaign manager Melissa Lavasani. “You shouldn’t bear the repercussions of the drug war while you are healing yourself.”

Just getting on the ballot required an innovative change in normal grassroots signature-gathering tactics and an assist from the D.C. Council. Activists had planned to launch their campaign in March with traditional door-to-door canvassing and street-corner volunteers. But they decided to hold off as the coronavirus made inroads and the local infection numbers climbed. By April, it became clear the lockdown would last months and they decided to proceed anyway.

They briefly tried some door-to-door in the Capitol Hill neighborhood but found families under virus lockdown weren’t receptive to a stranger at the door with a clipboard. So they shifted tactics and appealed to the D.C. Council for help. The council, as part of a larger coronavirus relief package, approved a landmark set of changes allowing residents to download a copy of the petition, sign it and submit a picture of the signed paper.

Volunteers set up signature booths outside grocery stores, at polling stations on the day of Washington’s primary election and even at the site of the city’s ongoing protests over systemic racism and police brutality.

Organizers also mailed copies of the petition and detailed packages centering around Lavasani’s family and her story to about 220,000 households. A district government employee and a mother of two, she says she successfully treated post-partum depression that included suicidal thoughts with controlled doses of psilocybin mushrooms and another natural psychedelic called ayahuasca.

“I started micro-dosing with psilocybin and within a matter of days I felt like myself again,” she said. “It was really scary to know that if anybody found out I was doing this, I would lose everything.”

It’s a message that Lavasani believes will resonate in a nation reeling under the psychological burdens of an ongoing pandemic, nationwide protests over racial injustice and what promises to be the most divisive presidential election in living memory.

“We’re going to be in rough shape when we get through this, and we’re going to need all the help we can get,” she said.

It’s also a message that had gained a foothold within mainstream scientific circles. A growing body of work is looking at the effects of natural psychedelics to treat depression, trauma and addiction. Last year, Johns Hopkins University opened the Center for Psychedelic and Consciousness Research with plans to study the effects of psychedelics on ailments including anorexia and Alzheimer’s disease.

In an article, center director Roland Griffiths called natural psychedelics “a fascinating class of compounds” that can “produce a unique and profound change of consciousness over the course of just several hours.”

The proposed D.C. ballot initiative would apply to psilocybin mushrooms, iboga, mescaline and ayuhuasca but not to peyote or to human-made psychedelics like LSD. It would instruct the Metropolitan Police Department to treat such substances as a low priority. If successful, Lavasani said she envisions patients being able to consume such substances in controlled circumstances and in consultation with doctors or therapists.